[1] Weisman S M,Graham D Y.Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events[J].Arch Intern Med,2002,162:2197-2202. [2] Lanas A.Prevention and treatment of NSAID-induced gastroduodenal injury[J].Curr Treat Options Gastroenterol,2006,9:147-156. [3] Laine L.GI risk and risk factors of NSAIDs[J].Cardiovasc Pharmacol,2006,47 Suppl 1:S60-66. [4] 国家药典委员会.中国药典Ⅰ部[S].北京:化学工业出版社,2005:206. [5] Guth P H,AuresD,Panlsen G.Topica aspirin plus HCl gastric lesions in the rat [J].Gastroedterology,1979,76 (1):88-93. [6] James F,Fries M D,Catherine A,et al.Nonsteroidal anti-inflammatory drug associated gastropathy: incidence and risk factor models [J].Am J Med,1991,91:213-222. [7] 施文,王永铭,李端,等.非甾体类抗炎药不良反应43年间的国内文献源分析[J].复旦学报(医学版),2004,31(5):527-531. [8] 刘利.非甾体抗炎药的不良反应机制及用药安全[J].中国实用医药,2008,3(34):201-202. [9] 李静,颜彦,吕迁洲.特异性还氧酶-2抑制剂对胃肠道肾脏及心血管系统的安全性[J].中国医院药学杂志,2003,23(12):758-759. [10] 张彭,王孟春.非甾体抗炎药致胃肠道黏膜损伤的研究进展[J].实用药物与临床,2008,11(6):378-380. [11] Matsuda H, Li Y,Yoshikawa M.Roles of endogenous prostaglandins and nitric oxide in inhibitions of gastric emptying and accelerations of gastrointestinal transit by escins Ia, Ib, IIb in mice[J].Life Sci,2000, 66(3):41-46. [12] 洪缨,侯家玉.娑罗子抑制胃酸分泌的实验研究[J].中国药理与临床,1999,15(1):24-25. [13] 洪缨,侯家玉.娑罗子抑酸作用机理研究[J].北京中医药大学学报,1999,22(3):45-47. |